Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

I S Nijhof; L E Franssen; MD Levin; GMJ Bos; A. Broijl; Saskia Klein; H R Koene; AC Bloem; A Beeker; LM Faber; E van der Spek; PF Ypma; R Raymakers; DJ van Spronsen; PE Westerweel; R Oostvogels; J van Velzen; B van Kessel; T Mutis; Pieter Sonneveld; S Zweegman; HM Lokhorst; NWCJ v.d. Donk

doi:10.1182/blood-2016-07-729236

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

I S Nijhof, L E Franssen, MD Levin, GMJ Bos, A. Broijl, Saskia Klein, H R Koene, AC Bloem, A Beeker, LM Faber, E van der Spek, PF Ypma, R Raymakers, DJ van Spronsen, PE Westerweel, R Oostvogels, J van Velzen, B van Kessel, T Mutis, Pieter SonneveldS Zweegman, HM Lokhorst, NWCJ v.d. Donk

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

50 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2297-2306
Number of pages	10
Journal	Blood
Volume	128
Issue number	19
DOIs	https://doi.org/10.1182/blood-2016-07-729236
Publication status	Published - 2016

Research programs

EMC MM-02-41-03

Access to Document

10.1182/blood-2016-07-729236

Cite this

Nijhof, I. S., Franssen, L. E., Levin, MD., Bos, GMJ., Broijl, A., Klein, S., Koene, H. R., Bloem, AC., Beeker, A., Faber, LM., van der Spek, E., Ypma, PF., Raymakers, R., van Spronsen, DJ., Westerweel, PE., Oostvogels, R., van Velzen, J., van Kessel, B., Mutis, T., ... v.d. Donk, NWCJ. (2016). Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood, 128(19), 2297-2306. https://doi.org/10.1182/blood-2016-07-729236

@article{c823f65e554f4a0d93a3c20ec0768be0,

title = "Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma",

author = "Nijhof, {I S} and Franssen, {L E} and MD Levin and GMJ Bos and A. Broijl and Saskia Klein and Koene, {H R} and AC Bloem and A Beeker and LM Faber and {van der Spek}, E and PF Ypma and R Raymakers and {van Spronsen}, DJ and PE Westerweel and R Oostvogels and {van Velzen}, J and {van Kessel}, B and T Mutis and Pieter Sonneveld and S Zweegman and HM Lokhorst and {v.d. Donk}, NWCJ",

year = "2016",

doi = "10.1182/blood-2016-07-729236",

language = "Undefined/Unknown",

volume = "128",

pages = "2297--2306",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "19",

}

Nijhof, IS, Franssen, LE, Levin, MD, Bos, GMJ, Broijl, A, Klein, S, Koene, HR, Bloem, AC, Beeker, A, Faber, LM, van der Spek, E, Ypma, PF, Raymakers, R, van Spronsen, DJ, Westerweel, PE, Oostvogels, R, van Velzen, J, van Kessel, B, Mutis, T, Sonneveld, P, Zweegman, S, Lokhorst, HM & v.d. Donk, NWCJ 2016, 'Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma', Blood, vol. 128, no. 19, pp. 2297-2306. https://doi.org/10.1182/blood-2016-07-729236

TY - JOUR

T1 - Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

AU - Nijhof, I S

AU - Franssen, L E

AU - Levin, MD

AU - Bos, GMJ

AU - Broijl, A.

AU - Klein, Saskia

AU - Koene, H R

AU - Bloem, AC

AU - Beeker, A

AU - Faber, LM

AU - van der Spek, E

AU - Ypma, PF

AU - Raymakers, R

AU - van Spronsen, DJ

AU - Westerweel, PE

AU - Oostvogels, R

AU - van Velzen, J

AU - van Kessel, B

AU - Mutis, T

AU - Sonneveld, Pieter

AU - Zweegman, S

AU - Lokhorst, HM

AU - v.d. Donk, NWCJ

PY - 2016

Y1 - 2016

U2 - 10.1182/blood-2016-07-729236

DO - 10.1182/blood-2016-07-729236

M3 - Article

C2 - 27647864

SN - 0006-4971

VL - 128

SP - 2297

EP - 2306

JO - Blood

JF - Blood

IS - 19

ER -